Fulfilling the promise of insulin pump therapy in childhood diabetes
William V. Tamborlane,
Corresponding Author
William V. Tamborlane
Department of Pediatrics and the General Clinical Research Center, Yale University School of Medicine, New Haven, CT, USA
*William V. Tamborlane, MD Department of Pediatrics and the General Clinical Research Center Yale University School of Medicine New Haven CT 06520 USA e-mail: [email protected]Search for more papers by this authorWilliam V. Tamborlane,
Corresponding Author
William V. Tamborlane
Department of Pediatrics and the General Clinical Research Center, Yale University School of Medicine, New Haven, CT, USA
*William V. Tamborlane, MD Department of Pediatrics and the General Clinical Research Center Yale University School of Medicine New Haven CT 06520 USA e-mail: [email protected]Search for more papers by this authorAbstract
Abstract: Although insulin pump or continuous subcutaneous insulin infusion (CSII) treatment was first introduced more than 25 yr ago, very few children and adolescents with type 1 diabetes mellitus (T1DM) utilized this therapy until recently. In this paper, we review many of the early triumphs, as well as a number of unexpected obstacles that were encountered in applying CSII in the treatment of T1DM. Nevertheless, the greater urgency to obtain optimal control of diabetes following the Diabetes Control and Complications Trial (DCCT), the introduction of rapid-acting insulin analogs and improvements in pump technology have led to a sharp increase in the use of this therapy in youth with T1DM and, generally, favorable outcomes. Moreover, the recent introduction of continuous glucose monitoring systems (CGMSs) offers the prospect of finally realizing the full potential of insulin pump therapy to normalize hemoglobin A1c (HbAlc) levels with minimal risk of hypoglycemia.
References
- 1 Sacca L, Sherwin R, Hendler R, Felig P. Influence of continuous physiologic hyperinsulinemia on glucose kinetics and counterregulatory hormones in normal and diabetic humans. J Clin Invest 1979: 7: 849–857.
- 2 Tamborlane WV, Sherwin RS, Genel M, Felig P. Reduction to normal of plasma glucose in juvenile diabetics by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med 1979: 300: 573–578.
- 3 Tamborlane WV, Sherwin RS, Genel M, Felig P. Outpatient management of juvenile-onset diabetics with a portable subcutaneous insulin infusion pump. Am J Med 1980: 68: 190–196.
- 4 Tamborlane WV, Sherwin RS, Genel M, Felig P. Restoration of normal lipid and amino acid metabolism in diabetic patients treated with a portable insulin infusion pump. Lancet 1979: 1: 1258–1261.
- 5 Dunn FL, Pietri A, Raskin P. Plasma lipid and lipoprotein levels with continuous subcutaneous insulin infusion in type 1 diabetes mellitus. Ann Intern Med 1981: 95: 426–431.
- 6 Viberti GC, Pickup JC, Jarrett RJ, Keen H. Effect of control of blood glucose on urinary excretion of albumin and beta2 microglobulin in insulin-dependent diabetes. N Engl J Med 1979: 300: 638–641.
- 7 Gertner JM, Tamborlane WV, Horst R, Sherwin RS, Felig P, Genel M. Mineral metabolism in diabetes mellitus. Changes accompanying treatment with a portable subcutaneous insulin infusion system. J Clin Endocrinol Metab 1980: 50: 862–866.
- 8 Amiel SA, Sherwin RS, Hintz RL, Gertner JM, Press M, Tamborlane WV. Effect of diabetes and its control on insulin-like growth factors in the young subject with type 1 diabetes. Diabetes 1984: 33: 1175–1179.
- 9 White NH, Waltman SR, Krupin T, Santiago JV. Reversal of abnormalities in ocular fluorophotometry in insulin-dependent diabetes after five to nine months of improved metabolic control. Diabetes 1982: 31: 80–85.
- 10 The Kroc Study Group. Blood glucose control and the evolution of diabetic retinopathy and albuminuria: Multicenter randomized trial. N Engl J Med 1984: 311: 365–372.
- 11 The Dcct Research Group. The incidence and prognostic significance of early worsening of retinopathy with intensive versus conventional treatment in the DCCT. Arch Ophthalmol 1998: 116: 874–886.
- 12 The Dcct Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. N Engl J Med 1993: 329: 977–986.
- 13 The DCCT, Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. J Pediatr 1994: 125: 177–188.
- 14 DCCT/, EDIC, Study Group. The effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002: 287: 2563–2569.
- 15 Simonson D, Tamborlane WV, Sherwin RS, Defronzo R. Improved insulin sensitivity in type I diabetes after chronic insulin pump treatment. Diabetes 1985: 34 (Suppl. 3): 80–86.
- 16 Simonson DC, Tamborlane WV, Defronzo RA, Sherwin RS. Insulin pump treatment reduces counterregulatory hormone responses to hypoglycemia in type 1 diabetes. Ann Intern Med 1985: 103: 184–190.
- 17 Amiel SA, Tamborlane WV, Sherwin RS. Defective glucose counterregulation after strict glycemic control of insulin-dependent diabetes mellitus. N Engl J Med 1987: 316: 1376–1383.
- 18 Amiel SA, Sherwin RS, Simonson DC, Tamborlane WV. Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release. Diabetes 1988: 37: 901–907.
- 19 Cryer PE. Iatrogenic hypoglycemia as a cause of hypoglycemia-associated autonomic failure in IDDM: a vicious cycle. Diabetes 1992: 41: 255–260.
- 20 Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborlane WV. Impaired insulin action in puberty: a contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med 1986: 315: 215–219.
- 21 Amiel SA, Caprio S, Sherwin RS, Plewe G, Haymond MW, Tamborlane WV. Insulin resistance of puberty: a defect restricted to peripheral glucose metabolism. J Clin Endocrinol Metab 1991: 72: 277–282.
- 22 Caprio S, Plewe G, Diamond MP, Simonson DC, Boulware SD, Sherwin RS, Tamborlane WV. Increased insulin secretion in puberty: a compensatory response to reductions in insulin sensitivity. J Pediatr 1989: 114: 963–967.
- 23 Mohn A, Matyka K, Harris D, Ross K, Edge J, Dunger DB. Lispro or regular insulin for multiple injection therapy in adolescents: differences in the insulin and glucose levels overnight. Diabetes Care 1999: 23: 27–32.
- 24 Jones TW, Porter P, David EA et al. Suppressed epinephrine responses during sleep: a contributing factor to the risk of nocturnal hypoglycemia in insulin-dependent diabetes. N Engl J Med 1998: 338: 1657–1662.
- 25 Zinman B, Tildesley H, Chiasson TJ, Tsue E, Strack T. Insulin lispro in CSII. results of a double-blind crossover study. Diabetes 1997: 46: 440–443.
- 26 Heptulla RA, Rodriguez LM, Bomgaars L, Haymond MW. The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. Diabetes 2005: 54: 1100–1107.
- 27 Grey M, Boland EA, Davidson M, Li J, Tamborlane W. Coping skills training for youth on intensive therapy has long lasting effects on metabolic control and quality of life. J Pediatr 2000: 137: 107–113.
- 28 Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. Continuous subcutaneous insulin infusion. A new way to achieve strict metabolic control, decrease severe hypoglycemia and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999: 22: 1779–1784.
- 29 Ahern JH, Boland EA, Doane R, Vincent M, Tamborlane WV. Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups. Pediatr Diabetes 2002: 3: 10–15.
- 30 Weinzimer SA, Ahern JH, Doyle EA, Dzuria J, Steffen AL, Tamborlane WV. Persistence of benefits of continuous subcutaneous insulin infusion (CSII) in very young children with type 1 diabetes mellitus. Pediatrics 2004: 114: 1601–1605.
- 31 Ahern JA, Ramchandani N, Caprio J, Himmel A, Silver D, Tamborlane WV. Using a primary nurse manager to implement DCCT recommendations in a larger pediatric program. Diabetes Educ 2000: 26: 990–994.
- 32 Diabetes Research in Children Network (DirecNet) Study Group. The accuracy of the CGMS in children with type 1 diabetes: results of the Diabetes Research in Children Network (DirecNet) accuracy study. Diabetes Technol Ther 2003: 5: 781–789.
- 33 Diabetes Research in Children Network (DirecNet) Study Group. The accuracy of the GlucoWatch G2 biographer in children with type 1 diabetes: results of the Diabetes Research in Children Network (DirecNet) accuracy study. Diabetes Technol Ther 2003: 5: 791–800.
- 34 Diabetes Research in Children Network (DirecNet) Study Group. A multicenter study of the accuracy of the One Touch Ultra home glucose meter in children with type 1 diabetes. Diabetes Technol Ther 2003: 5: 933–941.
- 35 The DirecNet Study Group. A randomized multicenter trial comparing the GlucoWatch Biographer with standard glucose monitoring in children with type 1 diabetes. Diabetes Care 2005: 28: 1101–1106.
- 36 The DirecNet Study Group. Accuracy of the modified Continuous Glucose Monitoring System (CGMS) sensor in an outpatient setting: results from a Diabetes Research in Children Network (DirecNet) study. Diabetes Technol Ther 2005: 7: 109–114.
- 37 Steil GM, Rebrin K, Hariri F, Chen Y-L, Darwin C, Saad MF. Continuous automated insulin delivery based on subcutaneous glucose sensing and an external insulin pump. Diabetes 2004: 53 (Suppl. 2): Abstract O10.
